Plexera, JPT Sign Distribution, Proteomics Application Development Agreement
NEW YORK (GenomeWeb) – Plexera Biotechnology and JPT Peptide Technologies today announced a deal to distribute JPT's peptide-based products and services in China and to develop peptide-based applications on Plexera's PlexArray HT platform for high-throughput proteomics screening.
Plexera will distribute JPT's products and services to the Chinese proteomics, immunotherapy, and vaccine markets, the companies said. Financial and other terms of the agreement were not disclosed.
"This partnership represents a strategic cornerstone in our continued efforts to address all major global markets with our broad portfolio of proprietary and high-quality products for the discovery of novel biomarkers and the development of immunotherapies and vaccines," JPT CEO Holger Wenschuh said in a statement.
JPT is a subsidiary of BioNTech and is based in Berlin. Its key technologies include PepStar for high-content peptide microarrays and SpikeTide for protein biomarker quantification.
Plexera, headquartered in Woodinville, Wash., provides surface plasmon resonance imaging-based solutions for chemical and biological applications.